Spanish nutraceuticals company Puleva Biotech, a unit of food major Ebro Puleva, has reported a 7% decline to €716,000 (US$873,000) in first half operating profits, hurt by large expenses to promote its new GH-28 probiotics line.
Net profits also fell 23% to €628,000 on revenues up 12% to €3.76m, the company said in a statement.
While turnover was boosted by brisk sales of its CV-17 “Omega3” fatty acid it was not enough to offset high costs to market GH-28 in the international markets before its slated launch later this year.
Puleva Biotech said its third-party research business performed well in the period. The unit is developing functional compounds for Ebro’s milk brand Lactimilk and for Ebro’s rice franchise.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData